# A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

> **NCT04994535** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 426 (actual)

## Conditions studied

- Platysma Prominence

## Interventions

- **DRUG:** OnabotulinumtoxinA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04994535
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-10
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04994535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04994535, "A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04994535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*